Erdafitinib,Vinflunine,Docetaxel,Pembrolizumab
Janssen,pierre fabre,Merck
['urothelial']
the thor phase iii trial concludes that erdafinitib is a standard of care option for patients with egfr-impaired metastatic urothelial cancer after ici treatment. #asco2023 #asco23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.